Senzime AB (publ)
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Senzime AB (publ) is a Swedish medical device company headquartered in Uppsala, specializing in the development, manufacturing, and marketing of advanced algorithm-powered patient monitoring systems designed to enhance patient safety during and after surgery. Its core products include the TetraGraph system, a quantitative neuromuscular transmission monitor supporting neuromuscular blockade management from induction to recovery; the ExSpiron 2Xi, a non-invasive respiratory monitoring system using bioelectrical impedance technology; and bedside systems such as the CliniSenz Analyzer and OnZurf Probe, which enable continuous automated measurement of critical biological compounds like glucose and lactate in blood and tissues. These products are CE- and FDA-cleared and are commercialized across over 30 countries, including direct sales operations in the United States and Germany. In recent developments, Senzime completed the acquisition of Respiratory Motion, Inc. in July 2022 for an initial consideration of $44 million, expanding its technology portfolio and market reach in Europe, China, and the United States. The company secured several significant contracts in the US, including system-wide agreements with major healthcare systems such as a Pacific Northwest hospital network and a large university hospital network in Texas, involving the supply of advanced TetraGraph monitors and scientific collaborations focused on quality improvement in anesthesia care. Furthermore, Senzime has expanded its commercial capabilities in the US with increased sales personnel and distribution agreements. The company also signed strategic connectivity and licensing partnerships, notably with Masimo for integrating its products into Masimo's Root patient monitoring system, and with Fukuda Denshi Co. Ltd. for licensing TetraGraph technology in Japan. Senzime reported a 65% growth in sales in 2024, driven by increased demand for disposable sensors, successful launch and market adoption of the next-generation TetraGraph system, and growth in Asian markets such as Japan and South Korea, supported by enhanced reimbursement frameworks and utilization of installed base products. Its technology is based on over 40 years of scientific research, targeting over 100 million surgical patients globally and aiming to set new standards in perioperative patient monitoring. The company was founded in 1999 and targets hospital and healthcare facility markets focusing on perioperative and postoperative patient safety monitoring solutions. Senzime operates primarily within the medical device and healthcare technology segments, serving hospitals and surgical centers worldwide, with an emphasis on advanced patient monitoring technologies that integrate digital health and algorithmic precision to support clinical decision-making and improve outcomes during anesthesia and recovery phases. This comprehensive approach underscores Senzime's position as a leader in perioperative patient safety innovation with notable strategic expansions and partnerships advancing its global reach and product offerings.
Senzime AB (publ) (SNZZF) Q2 2026 Earnings Call Transcript
Senzime AB (publ) (SNZZF) Q2 2026 Earnings Call Prepared Remarks Transcript
Interim Report Q2 2026: Strong Sensor Sales and Improved Margins, Despite Continued U.S. Monitor Market Headwinds
Senzime and Philips Medical Systems Enter Development and Commercialization Partnership
Invitation to Presentations of Senzime's Second Quarter 2026 Report
Senzime's TetraGraph System Receives ANVISA Regulatory Approval in Brazil
Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026
Senzime Strengthens Position in Pediatric Anesthesia by Securing Another Hospital Contract and Highlighting Positive Outcome Data
Senzime Advances Sustainable Anesthesia Monitoring with Launch of New EMG Sensor
From Science to Practice: Senzime Obtains FDA 510(k) Clearance for Enhanced TetraGraph System
Bulletin From Annual General Meeting in Senzime AB (publ)
Senzime Strengthens U.S. Operations with New Leadership Appointments
Senzime AB (publ) (SNZZF) Q1 2026 Earnings Call Transcript
Senzime AB (publ) (SNZZF) Q1 2026 Earnings Call Prepared Remarks Transcript
Margins Strengthened and Cash Flow Improved Despite a Temporary Dip in The Growth Trajectory. Full-Year Targets Remain on Track
Senzime Wins Expanded Contract Within Leading Southeastern US Hospital System
Notice of Annual General Meeting in Senzime AB (publ)
Invitation to Presentations of Senzime's First Quarter 2026 Report
Senzime Secures Strategic Hospital Orders Within Leading US Integrated Healthcare Delivery Network
Senzime AB (publ) (SNZZF) Q4 2025 Earnings Call Transcript